Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
Nirav N. Shah(Medical College of Wisconsin), Talha Munir(Leeds Teaching Hospitals NHS Trust), Sarah G. Injac(Baylor College of Medicine), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), John C. Byrd(University of Cincinnati), Francesco Forconi(University of Leeds), Shuo Ma(Nantong University), Dima El‐Sharkawi(Royal Marsden Hospital), Zulfa Omer(University of Cincinnati), Alvaro J. Alencar(University of Miami), Graham P. Collins(Churchill Hospital), Emma Searle(University of Manchester)
Cited by 27
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|215
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213